  | Esser, N., Mongovin, S. M., Parilla, J., Barrow, B. M., Mundinger, T. O., Fountaine, B. S., Larmore, M. J., Castillo, J. J., Akter, R., Hull, R. L., & Zraika, S. (01 March 2022). Neprilysin inhibition improves intravenous but not oral glucose-mediated insulin secretion via GLP-1R signaling in mice with β-cell dysfunction. American Journal of Physiology - Endocrinology and Metabolism, 322 (3), 307-E318. doi:10.1152/ajpendo.00234.2021  Peer Reviewed verified by ORBi |
 | Kahn, S. E., Chen, Y.-C., Esser, N., Taylor, A. J., van Raalte, D. H., Zraika, S., & Verchere, C. B. (2021). The β Cell in Diabetes: Integrating Biomarkers With Functional Measures. Endocrine Reviews, 42 (5), 528-583. doi:10.1210/endrev/bnab021 Peer Reviewed verified by ORBi |
 | Esser, N., Utzschneider, K. M., & Kahn, S. E. (2020). Early beta cell dysfunction vs insulin hypersecretion as the primary event in the pathogenesis of dysglycaemia. Diabetologia, 63 (10), 2007-2021. doi:10.1007/s00125-020-05245-x Peer Reviewed verified by ORBi |
  | ESSER, N., Legrand, S., Piette, J., SCHEEN, A., & PAQUOT, N. (2014). Inflammation as a link between obesity, metabolic syndrome and type 2 diabetes. Diabetes Research and Clinical Practice. doi:10.1016/j.diabres.2014.04.006 Peer Reviewed verified by ORBi |
 | ESSER, N., L'Homme, L., DE ROOVER, A., KOHNEN, L., SCHEEN, A., MOUTSCHEN, M., Piette, J., Legrand-Poels, S., & PAQUOT, N. (November 2013). Obesity phenotype is related to NLRP3 inflammasome activity and immunological profile of visceral adipose tissue. Diabetologia, 56, 2487-2497. doi:10.1007/s00125-013-3023-9 Peer Reviewed verified by ORBi |
 | Esser, N., Hogan, M. F., Templin, A. T., Akter, R., Fountaine, B. S., Castillo, J. J., El-Osta, A., Manathunga, L., Zhyvoloup, A., Raleigh, D. P., Zraika, S., Hull, R. L., & Kahn, S. E. (September 2024). The Islet Tissue Plasminogen Activator/Plasmin System is Upregulated with Human Islet Amyloid Polypeptide Aggregation and Protects Beta Cells from Aggregation-Induced Toxicity. Diabetologia, 67 (9), 1897-1911. doi:10.1007/s00125-024-06161-0 Peer Reviewed verified by ORBi |
 | L'homme, L., Sermikli, B. P., Haas, J. T., Fleury, S., Quemener, S., Guinot, V., Barreby, E., Esser, N., Caiazzo, R., Verkindt, H., Legendre, B., Raverdy, V., Cheval, L., Paquot, N., Piette, J., Legrand, S., Aouadi, M., Pattou, F., Staels, B., & Dombrowicz, D. (21 August 2024). Adipose tissue macrophage infiltration and hepatocyte stress increase GDF-15 throughout development of obesity to MASH. Nature Communications, 15 (1), 7173. doi:10.1038/s41467-024-51078-2 Peer Reviewed verified by ORBi |
 | Esser, N., Mongovin, S. M., Barrow, B. M., & Zraika, S. (02 July 2024). Gut-Specific Neprilysin Deletion Protects Against Fat-Induced Insulin Secretory Dysfunction In Male Mice. Endocrinology, 165 (8), 080. doi:10.1210/endocr/bqae080 Peer Reviewed verified by ORBi |
 | Scheen, A., Luyckx, F., Esser, N., & Paquot, N. (March 2024). Vignette diagnostique de l’étudiant. Ne pas négliger le syndrome métabolique. Revue Médicale de Liège, 79 (3), 191 - 194. Editorial Reviewed verified by ORBi |
 | Mukherjee, N., Contreras, C. J., Lin, L., Colglazier, K. A., Mather, E. G., Kalwat, M. A., Esser, N., Kahn, S. E., & Templin, A. T. (11 January 2024). RIPK3 promotes islet amyloid-induced β-cell loss and glucose intolerance in a humanized mouse model of type 2 diabetes. Molecular Metabolism, 80, 101877. doi:10.1016/j.molmet.2024.101877 Peer Reviewed verified by ORBi |
 | Esser, N., & Paquot, N. (23 August 2023). Actualisation des recommandations nutritionnelles dans le traitement du diabète de type 2. Revue Médicale Suisse, 19 (838), 1486 - 1490. doi:10.53738/REVMED.2023.19.838.1486 Peer Reviewed verified by ORBi |
 | Esser, N., Mongovin, S. M., Mundinger, T. O., Barrow, B. M., & Zraika, S. (10 August 2023). Neprilysin deficiency reduces hepatic gluconeogenesis in high fat-fed mice. Peptides, 168, 171076. doi:10.1016/j.peptides.2023.171076 Peer Reviewed verified by ORBi |
 | Esser, N., Mundinger, T. O., Barrow, B. M., & Zraika, S. (13 March 2023). Acute Inhibition of Intestinal Neprilysin Enhances Insulin Secretion via GLP-1 Receptor Signaling in Male Mice. Endocrinology, 164 (5). doi:10.1210/endocr/bqad055 Peer Reviewed verified by ORBi |
 | Castillo, J. J., Aplin, A. C., Hackney, D. J., Hogan, M. F., Esser, N., Templin, A. T., Akter, R., Kahn, S. E., Raleigh, D. P., Zraika, S., & Hull, R. L. (October 2022). Islet amyloid polypeptide aggregation exerts cytotoxic and proinflammatory effects on the islet vasculature in mice. Diabetologia, 65 (10), 1687 - 1700. doi:10.1007/s00125-022-05756-9 Peer Reviewed verified by ORBi |
 | SCHEEN, A., LUYCKX, F., Esser, N., LAMPROYE, A., DELWAIDE, J., & PAQUOT, N. (May 2022). Stéatohépatite non alcoolique (NASH) : un modèle d’inflammation métabolique («métaflammation»). Revue Médicale de Liège, 77 (5-6), 316-322. Editorial Reviewed verified by ORBi |
 | Esser, N., & PAQUOT, N. (May 2022). Inflammation, obésité et diabète de type 2. Rôle de l’inflammasome NLRP3 et du microbiote intestinal. Revue Médicale de Liège, 77 (5-6), 310-315. Editorial Reviewed verified by ORBi |
| Esser, N., Mongovin, S. M., Parilla, J., Barrow, B. M., Mundinger, T. O., Fountaine, B. S., Larmore, M. J., Castillo, J. J., Akter, R., Hull, R. L., & Zraika, S. (01 March 2022). Neprilysin inhibition improves intravenous but not oral glucose-mediated insulin secretion via GLP-1R signaling in mice with β-cell dysfunction. American Journal of Physiology - Endocrinology and Metabolism, 322 (3), 307-E318. doi:10.1152/ajpendo.00234.2021 Peer Reviewed verified by ORBi |
 | Esser, N., Schmidt, C., Barrow, B. M., Cronic, L., Hackney, D. J., Mongovin, S. M., Hogan, M. F., Templin, A. T., Castillo, J. J., Hull, R. L., & Zraika, S. (2022). Insulinotropic Effects of Neprilysin and/or Angiotensin Receptor Inhibition in Mice. Frontiers in Endocrinology, 13, 888867. doi:10.3389/fendo.2022.888867 Peer Reviewed verified by ORBi |
 | Wilkin, C., Colonval, M., Dehairs, J., Esser, N., Iovino, M., Gianfrancesco, M. A., FADEUR, M., Swinnen, J. V., PAQUOT, N., Piette, J., & Legrand, S. (2021). New insights on the PBMCs phospholipidome in obesity demonstrate modulations associated with insulin resistance and glycemic status. Nutrients. doi:10.3390/nu13103461 Peer Reviewed verified by ORBi |
 | Templin, A. T., Schmidt, C., Hogan, M. F., Esser, N., Kitsis, R. N., Hull, R. L., Zraika, S., & Kahn, S. E. (2021). Loss of apoptosis repressor with caspase recruitment domain (ARC) worsens high fat diet-induced hyperglycemia in mice. Journal of Endocrinology, 251 (2), 125-135. doi:10.1530/JOE-20-0612 Peer reviewed |
| Kahn, S. E., Chen, Y.-C., Esser, N., Taylor, A. J., van Raalte, D. H., Zraika, S., & Verchere, C. B. (2021). The β Cell in Diabetes: Integrating Biomarkers With Functional Measures. Endocrine Reviews, 42 (5), 528-583. doi:10.1210/endrev/bnab021 Peer Reviewed verified by ORBi |
 | Kjeldsen, S. A. S., Hansen, L. H., Esser, N., Mongovin, S., Winther-Sørensen, M., Galsgaard, K. D., Hunt, J. E., Kissow, H., Ceutz, F. R., Terzic, D., Mark, P. D., Plomgaard, P., Goetze, J. P., Goossens, G. H., Blaak, E. E., Deacon, C. F., Rosenkilde, M. M., Zraika, S., Holst, J. J., & Wewer Albrechtsen, N. J. (2021). Neprilysin Inhibition Increases Glucagon Levels in Humans and Mice With Potential Effects on Amino Acid Metabolism. Journal of the Endocrine Society, 5 (9), 084. doi:10.1210/jendso/bvab084 Peer Reviewed verified by ORBi |
 | Hogan, M. F., Hackney, D. J., Aplin, A. C., Mundinger, T. O., Larmore, M. J., Castillo, J. J., Esser, N., Zraika, S., & Hull, R. L. (2021). SGLT2-i improves markers of islet endothelial cell function in db/db diabetic mice. Journal of Endocrinology, 248 (2), 95-106. doi:10.1530/JOE-20-0354 Peer reviewed |
 | Esser, N., Utzschneider, K. M., & Kahn, S. E. (2021). On the causal relationships between hyperinsulinaemia, insulin resistance, obesity and dysglycaemia in type 2 diabetes: Reply to Johnson JD [letter]. Diabetologia, 64 (10), 2345-2347. doi:10.1007/s00125-021-05511-6 Peer Reviewed verified by ORBi |
 | Esser, N., & PAQUOT, N. (2021). Intérêt de la combinaison sacubitril/valsartan dans le diabète de type 2. Revue Médicale Suisse, 17, 1418-1422. Peer Reviewed verified by ORBi |
 | Templin, A. T., Mellati, M., Meier, D. T., Esser, N., Hogan, M. F., Castillo, J. J., Akter, R., Raleigh, D. P., Zraika, S., Hull, R. L., & Kahn, S. E. (2020). Low concentration IL-1β promotes islet amyloid formation by increasing hIAPP release from humanised mouse islets in vitro. Diabetologia, 63 (11), 2385-2395. doi:10.1007/s00125-020-05232-2 Peer Reviewed verified by ORBi |
| Esser, N., Utzschneider, K. M., & Kahn, S. E. (2020). Early beta cell dysfunction vs insulin hypersecretion as the primary event in the pathogenesis of dysglycaemia. Diabetologia, 63 (10), 2007-2021. doi:10.1007/s00125-020-05245-x Peer Reviewed verified by ORBi |
 | Esser, N., & Zraika, S. (2020). Neprilysin Inhibitors and Angiotensin(1-7) in COVID-19. British Journal of Cardiology, 27 (4), 109-111. doi:10.5837/bjc.2020.031 Peer Reviewed verified by ORBi |
 | Templin, A. T., Mellati, M., Soininen, R., Hogan, M. F., Esser, N., Castillo, J. J., Zraika, S., Kahn, S. E., & Hull, R. L. (2019). Loss of perlecan heparan sulfate glycosaminoglycans lowers body weight and decreases islet amyloid deposition in human islet amyloid polypeptide transgenic mice. Protein Engineering, Design and Selection, 32 (2), 95-102. doi:10.1093/protein/gzz041 Peer reviewed |
 | Hogan, M. F., Ziemann, M., K N, H., Rodriguez, H., Kaspi, A., Esser, N., Templin, A. T., El-Osta, A., & Kahn, S. E. (2019). RNA-seq-based identification of Star upregulation by islet amyloid formation. Protein Engineering, Design and Selection, 32 (2), 67-76. doi:10.1093/protein/gzz022 Peer reviewed |
 | Esser, N., & Zraika, S. (2019). Neprilysin inhibition: a new therapeutic option for type 2 diabetes? Diabetologia, 62 (7), 1113-1122. doi:10.1007/s00125-019-4889-y Peer Reviewed verified by ORBi |
 | Esser, N., Barrow, B. M., Choung, E., Shen, N. J., & Zraika, S. (2018). Neprilysin inhibition in mouse islets enhances insulin secretion in a GLP-1 receptor dependent manner. Islets, 10 (5), 175-180. doi:10.1080/19382014.2018.1502521 Peer Reviewed verified by ORBi |
 | Scheen, A., ESSER, N., & Paquot, N. (2015). Antidiabetic agents: Potential anti-inflammatory activity beyond glucose control. Diabetes and Metabolism. doi:10.1016/j.diabet.2015.02.003 Peer Reviewed verified by ORBi |
 | Esser, N., Paquot, N., & Scheen, A. (2015). Anti-inflammatory agents to treat or prevent type 2 diabetes, metabolic syndrome and cardiovascular disease. Expert Opinion on Investigational Drugs, 24 (3), 283-307. doi:10.1517/13543784.2015.974804 Peer Reviewed verified by ORBi |
 | ESSER, N., Paquot, N., & Scheen, A. (2015). Inflammatory markers and cardiometabolic diseases. Acta Clinica Belgica, 70 (3), 193-9. doi:10.1179/2295333715Y.0000000004 Peer Reviewed verified by ORBi |
 | Legrand-Poels, S., Esser, N., L'Homme, L., SCHEEN, A., PAQUOT, N., & Piette, J. (2014). Free fatty acids as modulators of the NLRP3 inflammasome in obesity / type 2 diabetes. Biochemical Pharmacology. doi:10.1016/j.bcp.2014.08.013 Peer Reviewed verified by ORBi |
| Esser, N., SCHEEN, A., & PAQUOT, N. (01 April 2014). Metabolically healthy overweight and obesity. Annals of Internal Medicine, 160 (7), 514. Peer Reviewed verified by ORBi |
| ESSER, N., Legrand, S., Piette, J., SCHEEN, A., & PAQUOT, N. (2014). Inflammation as a link between obesity, metabolic syndrome and type 2 diabetes. Diabetes Research and Clinical Practice. doi:10.1016/j.diabres.2014.04.006 Peer Reviewed verified by ORBi |
 | ESSER, N., Legrand-Poels, S., Piette, J., Paquot, N., & Scheen, A. (2014). Inflammasome NLRP3 et graisse viscerale. Revue Médicale de Liège, 69 Spec No, 57-61. Peer reviewed |
 | L'Homme, L., Esser, N., Riva, L., Scheen, A., Paquot, N., Piette, J., & Legrand, S. (November 2013). Unsaturated fatty acids prevent activation of NLRP3 inflammasome in human monocytes/macrophages. Journal of Lipid Research, 54, 2998-3008. doi:10.1194/jlr.M037861 Peer Reviewed verified by ORBi |
| ESSER, N., L'Homme, L., DE ROOVER, A., KOHNEN, L., SCHEEN, A., MOUTSCHEN, M., Piette, J., Legrand-Poels, S., & PAQUOT, N. (November 2013). Obesity phenotype is related to NLRP3 inflammasome activity and immunological profile of visceral adipose tissue. Diabetologia, 56, 2487-2497. doi:10.1007/s00125-013-3023-9 Peer Reviewed verified by ORBi |
 | DE SENY, D., COBRAIVILLE, G., CHARLIER, E., NEUVILLE, S., Esser, N., MALAISE, D., MALAISE, O., Calvo, F., RELIC, B., & MALAISE, M. (2013). Acute-phase serum amyloid a in osteoarthritis: regulatory mechanism and proinflammatory properties. PLoS ONE. doi:10.1371/journal.pone.0066769 Peer Reviewed verified by ORBi |
 | DE FLINES, J., RORIVE, M., Esser, N., Paquot, N., Luyckx, F., & SCHEEN, A. (2013). La vignette diagnostique de l'etudiant. Mise au point d'un patient consultant pour obesite. Revue Médicale de Liège, 68 (3), 148-53. Peer reviewed |
 | Esser, N., Paquot, N., & SCHEEN, A. (2011). Diabete de type 2 et medicaments anti-inflammatoires: nouvelles perspectives therapeutiques? Revue Médicale Suisse, 7 (306), 1614-8, 1620. Peer Reviewed verified by ORBi |
 | Esser, N., Paquot, N., & Scheen, A. (2010). Aptitude physique versus adiposité : aspects physiopathologiques et impacts cardio-métaboliques chez le sujet adulte non diabétique. Médecine des Maladies Métaboliques, 4, 291-298. doi:10.1016/S1957-2557(10)70062-6 Peer Reviewed verified by ORBi |
 | Esser, N., Paquot, N., & Scheen, A. (2010). Aptitude physique versus adiposité : impacts cardio-métaboliques respectifs chez l’enfant/adolescent et chez la personne âgée. Médecine des Maladies Métaboliques, 4, 395-401. doi:10.1016/S1957-2557(10)70083-3 Peer Reviewed verified by ORBi |
 | ESSER, N., Paquot, N., & Scheen, A. (2010). "Fitness" versus "fatness": impacts cardio-metaboliques respectifs aux differents ages de la vie. Revue Médicale de Liège, 65 (4), 199-205. Peer reviewed |
 | ESSER, N., Paquot, N., & Scheen, A. (March 2009). Sujets « métaboliquement sains », bien qu’obèses. Première partie: diagnostic, physiopathologie et prévalence. Obésité: Revue Francophone pour la Recherche Clinique, la Prévention et la Prise en Charge de l'Obésité, 3, 56-65. doi:10.1007/s11690-009-0170-8 Peer Reviewed verified by ORBi |
 | ESSER, N., & Scheen, A. (2009). Sujets obèses sans anomalies métaboliques. Revue Médicale de Liège, 64 (3), 148-157. Peer reviewed |
 | Beck, E., ESSER, N., Paquot, N., & Scheen, A. (2009). Sujets de poids normal «métaboliquement obèses» et sujets obèses «métaboliquement sains». Revue Médicale de la Suisse Romande, 5, 1644-1649. Peer Reviewed verified by ORBi |
 | Esser, N., PAQUOT, N., & SCHEEN, A. (2009). Sujets « métaboliquement sains », bien qu’obèses 2ème partie : pronostic et prise en charge. Obésité: Revue Francophone pour la Recherche Clinique, la Prévention et la Prise en Charge de l'Obésité, 4, 134-141. doi:10.1007/s11690-009-0188-y Peer Reviewed verified by ORBi |
| Esser, N. (2023). Gut-Specific Neprilysin Deletion Increases Insulin Secretion in High-Fat–Fed Mice. Diabetes, 72(Supplement_1), 1546. Peer Reviewed verified by ORBi Dataset: https://doi.org/10.2337/db23-1546-P |
 | Esser, N., Hogan, M. F., Templin, A. T., Akter, R., Castillo, J. J., Raleigh, D. P., Zraika, S., Hull, R. L., & Kahn, S. E. (September 2022). Islet macrophage depletion does not prevent amyloid-induced upregulation of tissue plasminogen activator (tPA). Diabetologia, 65 (Suppl 1), 1-1469. Peer Reviewed verified by ORBi |
 | AKTER, R., HOGAN, M. F., Esser, N., CASTILLO, J. J., HULL-MEICHLE, R. L., ZRAIKA, S., & KAHN, S. E. (01 June 2022). Cholesterol Accumulation in Islets Increases Steroidogenic Acute Regulatory (StAR) Protein Expression and Decreases Islet Cell Viability and ß-Cell Function. Diabetes, 71 (Supplement_1), 1457. doi:10.2337/db22-1457-p Peer Reviewed verified by ORBi |
 | HOGAN, M. F., Esser, N., TEMPLIN, A. T., CASTILLO, J. J., AKTER, R., HULL, R. L., KAHN, S. E., & ZRAIKA, S. (01 June 2021). Statin Exposure Increases Star (Steroidogenic Acute Regulatory Protein) Expression in Islets: A Novel Mechanism for ß-Cell Dysfunction and Increased Diabetes Risk? Diabetes, 70 (Supplement_1), 130. doi:10.2337/db21-130-or Peer Reviewed verified by ORBi |
 | Castillo, J. J., Aplin, A., Hogan, M. F., Templin, A. T., Esser, N., Akter, R., & Hull, R. L. (2021). The Proinflammatory but Not Cytotoxic Effect of Aggregated IAPP on Islet Endothelial Cells Requires TLR2/4 Signaling. Diabetes, 70 (Suppl 1), 1238. Peer Reviewed verified by ORBi |
 | Castillo, J. J., Hogan, M. F., Aplin, A., Esser, N., Templin, A. T., Hull, R. L., Zraika, S., & Kahn, S. E. (2020). Hyaluronan produced by inflamed islet endothelial cells contributes to hIAPP aggregation. Diabetes, 69 (Suppl 1), 2043. Peer Reviewed verified by ORBi |
 | Hogan, M. F., Esser, N., Templin, A. T., Castillo, J. J., Zraika, S., Hull, R. L., & Kahn, S. E. (2020). Chronic activation of CREB by islet amyloid increases Star (steroidogenic acute regulatory protein). Diabetes, 69 (Suppl 1), 2040. Peer Reviewed verified by ORBi |
 | Templin, A. T., Schmidt, C. R., Hogan, M. F., Esser, N., Kitsis, R., Hull, R. L., Zraika, S., & Kahn, S. E. (2020). Loss of apoptosis repressor with caspase recruitment domain promotes high-fat diet induced hyperglycemia in vivo. Diabetes, 69 (Suppl 1), 2042. Peer Reviewed verified by ORBi |
 | Esser, N., Schmidt, C. R., Barrow, B., Cronic, L., Hackney, D. J., Mongovin, S., Hull, R. L., & Zraika, S. (2020). Effect of LCZ696 and its components sacubitril and valsartan on insulin secretion and glucose homeostasis in mice. Diabetes, 69 (Suppl 1), 1797. Peer Reviewed verified by ORBi |
 | Esser, N., Hogan, M. F., Templin, A. T., Castillo, J. J., Raleigh, D., Edgar, J. S., Zraika, S., Hull, R. L., & Kahn, S. E. (2020). Plasmin-mediated cleavage of human islet amyloid polypeptide (hIAPP) protects beta-cells from amyloid-induced toxicity. Diabetes, 69 (Suppl 1), 2039. Peer Reviewed verified by ORBi |
 | Hogan, M. F., Esser, N., Templin, A. T., Zraika, S., Hull, R. L., El-Osta, S., & Kahn, S. E. (2019). Increased StAR (steroidogenic acute regulatory protein) is detrimental to ß cells and promotes mitochondrial dysfunction. Diabetes, 68 (Suppl 1), 2125. Peer Reviewed verified by ORBi |
 | Esser, N., Hogan, M. F., Aplin, A., Templin, A. T., El-Osta, S., Raleigh, D., Edgar, J. S., Zraika, S., Hull, R. L., & Kahn, S. E. (2019). The tissue plasminogen activator (tPA)/plasmin system reduces amyloid formation by cleaving human islet amyloid polypeptide (hIAPP). Diabetes, 68 (Suppl 1), 2124. Peer Reviewed verified by ORBi |
 | Templin, A. T., Mellati, M., Zeman-Meier, D., Hogan, M. F., Esser, N., Zraika, S., Hull, R. L., & Kahn, S. E. (2019). Physiological concentrations of IL-1 beta promote islet amyloid deposition by increasing beta-cell secretion of human islet amyloid polypeptide. Diabetes, 68 (Suppl 1), 2126. Peer Reviewed verified by ORBi |
 | Esser, N., Mundinger, T. O., Barrow, B., Mongovin, S., & Zraika, S. (2019). Acute inhibition of intestinal neprilysin enhances glucose-stimulated insulin secretion in mice. Diabetes, 68 (Suppl 1), 1829. Peer Reviewed verified by ORBi |
 | Esser, N., Hogan, M. F., Templin, A. T., Ziemann, M., El-Osta, A., Zraika, S., Hull, R. L., & Kahn, S. E. (2018). Tissue plasminogen activator (tPA) expression is increased by islet amyloid formation in vitro. Diabetes, 67 (Suppl 1), 2107. Peer Reviewed verified by ORBi |
 | Parilla, J. P., Mongovin, S., Barrow, B., Esser, N., & Zraika, S. (2018). Pharmacological neprilysin inhibition improves glucose homeostasis in a mouse model of type 2 diabetes. Diabetes, 67 (Suppl 1), 1825. Peer Reviewed verified by ORBi |
 | Gianfrancesco, M., Dehairs, J., L'Homme, L., Colonval, M., Piette, J., Swinnen, J., Paquot, N., Esser, N., & Legrand, S. (2017). The saturation of membrane phospholipids would be a trigger for K+ efflux and NLRP3 inflammasome activation in human monocytes/macrophages. Diabetologia. Peer Reviewed verified by ORBi |
 | Gianfrancesco, M., Dehairs, J., Bloch, K., L'homme, L., Piette, J., Swinnen, J., Paquot, N., Esser, N., & Legrand, S. (August 2016). Involvement of membrane remodelling induced by fatty acids in the regulation of the NLRP3 inflammasome activity in human macrophages. Diabetologia, 59 (Supplement 1), 291. Peer Reviewed verified by ORBi |
| Esser, N., L'Homme, L., DE ROOVER, A., KOHNEN, L., SCHEEN, A., MOUTSCHEN, M., Piette, J., Legrand-Poels, S., & PAQUOT, N. (2013). Increased Inflammasome and Caspase-1 Activation in Visceral adipose tissue from Metabolically Unhealthy Obese compared to Metabolically Healthy Obese subjects. Diabetes, (62/suppl.1), 555. Peer Reviewed verified by ORBi |
 | Esser, N., L'Homme, L., DE ROOVER, A., KOHNEN, L., SCHEEN, A., Moutschen, M., Piette, J., Legrand-Poels, S., & PAQUOT, N. (March 2013). Différences d’activité de l’inflammasome NLRP3 entre sujets obèses avec et sans anomalies métaboliques. Diabetes and Metabolism, 39 (suppl 1), 102. Peer Reviewed verified by ORBi |
Esser, N., Mongovin, S., Barrow, B. M., & Zraika, S. (21 March 2024). L’invalidation sélective de la néprilysine dans les entérocytes augmente la sécrétion d’insuline chez les souris sous régime riche en graisses [Paper presentation]. Congrès Annuel de la Société Francophone du Diabète, Toulouse, France. Peer reviewed |
| Esser, N., Hogan, M. F., Templin, A. T., Akter, R., Castillo, J. J., Zraika, S., Hull, R. L., & Kahn, S. E. (June 2022). Macrophage Depletion Does Not Prevent Tissue Plasminogen Activator (tPA) Upregulation in Islets with Amyloid Deposition [Poster presentation]. Cell Symposium: Translational Immunometabolism, Bâle, Switzerland. Peer reviewed |
Esser, N., Barrow, B. M., Mundinger, T. O., Parilla, J. H., & Zraika, S. (September 2018). Contribution of islet and intestinal neprilysin in modulating beta-cell function [Poster presentation]. The Islet Biology Workshop at Vanderbilt, Nashville, United States. Peer reviewed |
